Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
4,584.00    18.00 (0.39%)
Bid:
4,582.00
Ask:
4,584.00
Spread: 2.00 (0.044%)
Market Cap: £16.71b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Directorate Change

21 Jun 2017 09:26

RNS Number : 7109I
Coca-Cola HBC AG
21 June 2017
 

FOR IMMEDIATE RELEASE

 

Coca-Cola HBC AG

Composition of the Committees of the Board of Directors of Coca‑Cola HBC AG and determination of a new member of the Board of Directors of Coca‑Cola HBC AG

 

 

Zug, Switzerland - 21 June 2017 - Coca‑Cola HBC AG ("Coca‑Cola HBC" or the "Company") announces today that its board of directors (the "Board") has appointed Ms. Charlotte J. Boyle as a member of the Remuneration Committee, with effect from 20 June 2017.

This appointment has been made pursuant to the announcement released by Coca‑Cola HBC on 15 May 2017 and the election of Ms. Charlotte J. Boyle as a non-executive member of the Board at the Company's annual general meeting held on 20 June 2017, following the retirement of Mr. Antonio D'Amato.

The Board has determined that Ms. Charlotte J. Boyle qualifies as independent under the criteria set forth in the UK Corporate Governance Code.

Aside from the information set out above, no further information is required to be disclosed pursuant to the UK Financial Conduct Authority's Listing Rule 9.6.13 and the new non-executive director does not hold any interests in the shares of Coca‑Cola HBC.

The composition of the Board Committees will be as follows:

Audit Committee

William (Bill) W. Douglas III (Chair)

John P. Sechi

Olusola (Sola) David-Borha

Nomination Committee

Reto Francioni (Chair)

Charlotte J. Boyle

Alexandra Papalexopoulou

Remuneration Committee

Alexandra Papalexopoulou (Chair)

Charlotte J. Boyle

Reto Francioni

Social Responsibility Committee

Anastasios I. Leventis (Chair)

Alexandra Papalexopoulou

José Octavio Reyes

This announcement is made pursuant to Listing Rule 9.6.11.

 

 

 

Enquiries

Coca‑Cola HBC Group

Basak Kotler

Investor Relations Director

Tel: +44 20 37 444 231 basak.kotler@cchellenic.com

Vasso Aliferi

Investor Relations Manager

Tel: +30 210 6183 341

vasso.aliferi@cchellenic.com

Maria Livaniou

Head of Shareowner Service

Tel: +30 210 6183 106

maria.livaniou@cchellenic.com

 

International media contact:

Teneo Blue Rubicon

Rob Morgan

Anushka Mathew

Tel: +44 20 7260 2700 robert.morgan@teneobluerubicon.com anushka.mathew@teneobluerubicon.com

 

Greek media contact:

V+O Communications

Argyro Oikonomou

Tel: +30 211 7501219

 ao@vando.gr

 

 

About Coca‑Cola HBC

Coca-Cola HBC is a leading bottler of The Coca-Cola Company with a sales volume of more than 2 billion unit cases. It has a broad geographic footprint with operations in 28 countries serving a population of approximately 595 million people. Coca-Cola HBC offers a diverse range of non-alcoholic ready to drink beverages in the sparkling, juice, water, sport, energy, tea and coffee categories. Coca-Cola HBC is committed to promoting sustainable development in order to create value for its business and for society. This includes providing products that meet the beverage needs of consumers, fostering an open and inclusive work environment, conducting its business in ways that protect and preserve the environment and contribute to the socio-economic development of the local communities. Coca-Cola HBC is ranked beverage industry leader in the Dow Jones Sustainability World and Europe Indices, and is also included in the FTSE4Good Index.

 

Coca-Cola HBC has a premium listing on the London Stock Exchange (LSE: CCH) and its shares are listed on the Athens Exchange (ATHEX: EEE). For more information, please visit http://www.coca-colahellenic.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALIFFTRSILFID
Date   Source Headline
19th Mar 20251:00 pmRNSDirector/PDMR Shareholding
19th Mar 20251:00 pmRNSDirector/PDMR Shareholding
18th Mar 20251:21 pmRNSDirector/PDMR Shareholding
14th Mar 20253:45 pmRNSAnnual Financial Report
13th Mar 20252:18 pmRNSDirector/PDMR Shareholding
12th Mar 20259:22 amRNSDirector/PDMR Shareholding
11th Mar 202512:17 pmRNSDirector Declaration
5th Mar 20251:19 pmRNSDirector/PDMR Shareholding
4th Mar 20256:03 pmRNSTransfer of treasury shares and voting rights
4th Mar 20254:03 pmRNSDirector/PDMR Shareholding
26th Feb 202510:07 amRNSDirector/PDMR Shareholding
18th Feb 20251:50 pmRNSDirector/PDMR Shareholding
17th Feb 20259:22 amRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSStrong execution drove continued profitable growth
3rd Feb 202510:09 amRNSTransfer of treasury shares and voting rights
27th Jan 20253:13 pmRNSCorrection - Total voting rights
20th Jan 20251:49 pmRNSDirector/PDMR Shareholding
15th Jan 20251:55 pmRNSNotice of Results
3rd Jan 202511:51 amRNSTotal Voting Rights
2nd Jan 20259:16 amRNSDirector/PDMR Shareholding
18th Dec 20242:19 pmRNSDirector/PDMR Shareholding
17th Dec 20244:17 pmRNSDirector/PDMR Shareholding
17th Dec 20244:09 pmRNSDirector/PDMR Shareholding
17th Dec 20243:46 pmRNSHolding(s) in Company
4th Dec 202410:50 amRNSDirector/PDMR Shareholding
4th Dec 202410:28 amRNSDirector/PDMR Shareholding
2nd Dec 202410:35 amRNSTotal Voting Rights
29th Nov 20241:40 pmRNSDirector/PDMR Shareholding
29th Nov 202410:08 amRNSDirector/PDMR Shareholding
28th Nov 20248:41 amRNSDirector/PDMR Shareholding
28th Nov 20248:23 amRNSDirector/PDMR Shareholding
19th Nov 20243:51 pmRNSDirector/PDMR Shareholding
19th Nov 202411:14 amRNSFinal Terms - 2032 Notes
13th Nov 20244:41 pmRNSDirector Declaration
13th Nov 20244:11 pmRNSPricing of Issue of Notes
13th Nov 20248:39 amRNSIssue of Debt
12th Nov 20243:56 pmRNSPublication of Suppl.Prospcts
8th Nov 202410:27 amRNSNotice of purchase
7th Nov 202411:39 amRNSDirector/PDMR Shareholding
7th Nov 202411:36 amRNSDirector/PDMR Shareholding
1st Nov 202410:12 amRNSBlock listing Interim Review
31st Oct 20247:00 amRNSStrong execution drives continued growth
18th Oct 20243:36 pmRNSDirector/PDMR Shareholding
8th Oct 20241:06 pmRNSCCH holds webinar on Data, Insights and Analytics
4th Oct 20248:40 amRNSNotice of Results
1st Oct 20249:42 amRNSTotal Voting Rights
27th Sep 20245:17 pmRNSTransaction in Own Shares
26th Sep 20245:08 pmRNSTransaction in Own Shares
25th Sep 20245:06 pmRNSTransaction in Own Shares
23rd Sep 20245:05 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.